Zlatikha Djuliannisaa

Dr. Zlatikha Djuliannisaa

Universitas Indonesia, Depok, Jawa Barat, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CMCourtney McDonald
Courtney McDonald
ZDZlatikha Djuliannisaa
Zlatikha Djuliannisaa
MPMaria Petraki
Maria Petraki
Madison Claire Badawy PatonMadison Claire Badawy Paton
Madison Claire Badawy Paton
TPTayla R. Penny
Tayla R. Penny
Suzanne L MillerSuzanne L Miller
Suzanne L Miller
Cerebral palsy (CP) is a permanent motor disorder that results from brain injury and neuroinflammation during the perinatal period. Mesenchymal stromal cells (MSCs) have been explored as a therapy in multiple adult neuroinflammatory conditions. Our study examined the therapeutic benefits of intranasal delivery of human umbilical cord tissue (UC) derived-MSCs in a rat model of neonatal hypoxic–ischemic (HI) brain injury. To do this, HI was performed on postnatal day 10 Sprague-Dawley rat pups via permanent ligation of the left carotid artery, followed by a hypoxic challenge of 8% oxygen for 90 min. A total of 200,000 UC-MSCs (10 million/kg) were administered intranasally 24 h post-HI. Motor control was assessed after seven days, followed by post-mortem. Analysis included brain immunohistochemistry, gene analysis and serum cytokine measurement. Neonatal HI resulted in brain injury with significant loss of neurons, particularly in the hippocampus. Intranasal administration of UC-MSCs significantly reduced the loss of brain tissue and increased the number of hippocampal neurons. HI significantly upregulated brain inflammation and expression of pro-inflammatory cytokines, while intranasal UC-MSCs significantly reduced markers of neuroinflammation. This study demonstrated that a clinically relevant dose (10 million/kg) of UC-MSCs was neuroprotective following HI by restoring neuronal cell numbers and reducing brain inflammation. Therefore, intranasal delivery of UC-MSCs may be an effective therapy for neonatal brain injury.

30 May 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
RHRakhmad Hidayat
Rakhmad Hidayat
AMAlyssa Putri Mustika
Alyssa Putri Mustika
FAFhathia Avisha
Fhathia Avisha
ZDZlatikha Djuliannisaa
Zlatikha Djuliannisaa
DWDinisa Diah Winari
Dinisa Diah Winari
AGAstuti Giantini
Astuti Giantini
Facing the rising cases of with higher fatalities COVID-19, some countries decided to give the third dose of vaccine as a booster. As of 9 January 2022, 90.31% of health workers in Indonesia have received the third dose vaccine. This study aims to provide an evaluation of adverse events following immunization (AEFI) in a single center in Indonesia to form a basis for ensuring safety for booster administration nationally. A retrospective, cross-sectional study was conducted using an online survey. Demographic data, AEFI complaints, and factors influencing AEFIs were evaluated. In this study, there were a total of 311 subjects were gathered. The most common AEFI symptoms found at onset <24 h to 28 days were pain at the injection site, fever, shoulder pain, and headache. Most of the AEFI severity of <24 h to 28 days post-vaccination was grade 1 (reduced or uninterrupted daily activities). There was a significant correlation between AEFI and several factors, such as the history of drug allergy, exercise after vaccination, age, BMI < 25, history of symptoms after the first and second vaccinations, and history of COVID-19. There was no anaphylactic reaction in this study. Several AEFI should be considered for the third dose of COVID-19 vaccine administration.

24 August 2022 in Journal of Environmental and Public Health
Verified
Journal Article
Open access
PDF file
RHRakhmad Hidayat
Rakhmad Hidayat
ZDZlatikha Djuliannisaa
Zlatikha Djuliannisaa
AMAlyssa Putri Mustika
Alyssa Putri Mustika
GFGemia Clarisa Fathi
Gemia Clarisa Fathi
MAMuhammad Hafiz Aini
Muhammad Hafiz Aini
MPMuhammad Arza Putra
Muhammad Arza Putra
When the outbreak of the COVID‐19 delta variant occurred in June 2021, there was a marked increase in Indonesia’s number of self‐isolated patients. The Universitas Indonesia Hospital provided a One‐Stop Service (OSS) to monitor COVID‐19 patients on self‐isolation. This study was conducted to determine the effectiveness of the self‐isolation monitoring performed by hospitals and the factors that determined the outcomes of patients on self‐isolation. This study was conducted using a cross‐sectional method based on secondary data from electronic medical records. Data analysis was performed by determining the relationship of patient risk factors and characteristics with COVID‐19 outcomes. The study found that poorer symptoms, administration of antibiotics, absence of shortness of breath, and normal ALT levels significantly improved the outcome of OSS patients. The study also suggested that during monitoring of patients on COVID‐19 self‐isolation, chest/thorax radiography is necessary. The self‐isolation monitoring program is essential to observe the patient’s condition and evaluate the possibility of deteriorating conditions that could lead to admission decisions in the early or middle stages of the program. This will be beneficial during pandemic emergencies.

30 October 2023 in Česká gynekologie
Verified
Journal Article
Closed access
SASiti Azizah
Siti Azizah
IHIndonesia Universitas Indonesia Hospital
Indonesia Universitas Indonesia Hospital
AMAlyssa Putri Mustika
Alyssa Putri Mustika
NWNïta Widjaya
Nïta Widjaya
RIRima Irwinda
Rima Irwinda
MJMaryam Jamilah
Maryam Jamilah
Background: The covid-19 pandemic may cause severe clinical manifestations in a vulnerable population, such as pregnant women. Based on Indonesian Obstetrics and Gynecology Association (POGI), the number of maternal deaths due to covid-19 from April 2020 to April 2021 reached 3% and increased to 9% since the delta variant of covid-19 emerged. This research was expected to identify factors that are related to the mortality rate of pregnant women with covid-19. Materials and methods: This was a cross-sectional study using secondary data collected from June 2020 to August 2021. The study was conducted in Universitas Indonesia Hospital, a national covid-19 referral hospital. Patient characteristics, pregnancy profile, comorbidities, laboratory results, chest X-ray examination, treatment options, and the severity of symptoms were evaluated. In addition, bivariate data analysis was carried out using the SPSS device. Results: Out of 114 research subjects, seven patients (6.1%) died, and 107 patients (93.9%) survived. The risk of mortality was significantly (P < 0.05) related to patients' age, duration of hospitalization, gestational age, severity rate of covid-19 , the level of hemoglobin, leukocyte count, platelet count, lymphocytes, the levels of D-dimer, C-reactive protein, transaminase enzymes, urea, creatinine, eGFR, sodium, potassium, and procalcitonin. In addition, significant differences (P < 0.05) related to maternal mortality rate were also shown in the presence of comorbidities (type 2 diabetes, congestive heart failure, coronary artery disease/ acute coronary syndrome, and urinary tract infection), and the use of steroids and tocilizumab. Conclusion: Various factors significantly related to the mortality rate of pregnant women with covid-19. This study may become the basis for a further study with a larger number of subjects, adjustment of assessment and management of covid-19 infected pregnant women, thus hopefully reducing the risk of mortality in pregnant women with covid-19.